Get the Stockscreener App
8.96
0.99%
-0.09
After Hours:
9.11
0.15
+1.67%
Precision Biosciences Inc stock is traded at $8.96, with a volume of 89,690.
It is down -0.99% in the last 24 hours and down -17.65% over the past month.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
See More
Previous Close:
$9.05
Open:
$8.96
24h Volume:
89,690
Relative Volume:
2.27
Market Cap:
$64.89M
Revenue:
$52.29M
Net Income/Loss:
$-73.52M
P/E Ratio:
-11.06
EPS:
-0.81
Net Cash Flow:
$-100.45M
1W Performance:
-4.48%
1M Performance:
-17.65%
6M Performance:
-33.92%
1Y Performance:
-12.49%
1-Day Range:
$8.80
$9.29
1-Week Range:
$8.80
$9.74
52-Week Range:
$8.25
$19.43
Precision Biosciences Inc Stock (DTIL) Company Profile
Name
Precision Biosciences Inc
Sector
Industry
Phone
919-314-5512
Address
302 EAST PETTIGREW STREET, DURHAM, NC
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-09-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-27-20 | Resumed | BTIG Research | Buy |
| Apr-03-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-05-20 | Initiated | Stifel | Buy |
| Feb-25-20 | Initiated | William Blair | Outperform |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | H.C. Wainwright | Buy |
| Apr-22-19 | Initiated | Barclays | Overweight |
| Apr-22-19 | Initiated | Goldman | Buy |
| Apr-22-19 | Initiated | JP Morgan | Overweight |
| Apr-22-19 | Initiated | Jefferies | Buy |
View All
Precision Biosciences Inc Stock (DTIL) Latest News
Precision Biosciences files CTAs for PBGENE-HBV for chronic HBV - BioWorld Online
Precision BioSciences files for gene editing trial - Investing.com
Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B - StockTitan
When (DTIL) Moves Investors should Listen - Stock Traders Daily
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - BioSpace
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Short Interest in Precision BioSciences, Inc. (NASDAQ:DTIL) Decreases By 8.0% - MarketBeat
Wall Street Analysts Think Precision BioSciences (DTIL) Could Surge 277.6%: Read This Before Placing a Bet - Yahoo Finance
Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution - BioSpace
Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution - StockTitan
Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution - Yahoo Finance
Despite Fast-paced Momentum, Precision BioSciences (DTIL) Is Still a Bargain Stock - Yahoo Finance
Global Genetic Engineering Market Size To Worth USD 8.95 Billion By 2033 | CAGR Of 20.82% - GlobeNewswire Inc.
Gene Editing Therapeutics Market Forecast 2024-2029: A $1 Billion Market by 2029, with a Forecasted CAGR of 147% - GlobeNewswire Inc.
Allogeneic CAR-T Azer-Cel Achieves Complete Responses in Some Patients With Diffuse Large B-Cell Lymphoma - CGTLive™
Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference - Yahoo Finance UK
Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference - Yahoo Finance
Precision BioSciences receives $13 million from Imugene - Investing.com India
Precision BioSciences receives $13 million from Imugene By Investing.com - Investing.com Australia
Precision BioSciences receives $13 million from Imugene By Investing.com - Investing.com Canada
Precision BioSciences Secures Funds, Bolsters Oncology Partnership - TipRanks
Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal - Yahoo Finance UK
Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal - Business Wire
Wall Street Analysts Believe Precision BioSciences (DTIL) Could Rally 307.93%: Here's is How to Trade - MSN
(DTIL) Technical Pivots with Risk Controls - Stock Traders Daily
Wall Street Analysts Believe Precision BioSciences (DTIL) Could Rally 307.93%: Here's is How to Trade - Yahoo Finance
Precision BioSciences, Inc. (NASDAQ:DTIL) Expected to Post FY2024 Earnings of $2.03 Per Share - MarketBeat
Precision BioSciences (NASDAQ:DTIL) Receives “Buy” Rating from HC Wainwright - Defense World
Precision BioSciences' (DTIL) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Vanguard Group Inc. Sells 4,493,945 Shares of Precision BioSciences, Inc. (NASDAQ:DTIL) - MarketBeat
Short Interest in Precision BioSciences, Inc. (NASDAQ:DTIL) Decreases By 8.8% - MarketBeat
TG Therapeutics Receives Clearance from FDA for Phase 1 Trial in Multiple Sclerosis for Allogeneic CAR-T Azer-Cel - CGTLive™
Azer-cel gets IND clearance in multiple sclerosis - BioWorld Online
Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis - 01Net
Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis - StockTitan
Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis - Business Wire
MBX Biosciences Raises $63.5 Million in Series C Financing - GlobeNewswire
Janus Henderson Group PLC Acquires New Holdings in Precision BioSciences, Inc. (NASDAQ:DTIL) - MarketBeat
Precision BioSciences (NASDAQ:DTIL) Issues Earnings Results - Defense World
Janus Henderson Group PLC Buys Shares of 573,052 Precision BioSciences, Inc. (NASDAQ:DTIL) - Defense World
Precision BioSciences (NASDAQ:DTIL) Releases Quarterly Earnings Results, Beats Expectations By $4.23 EPS - MarketBeat
Precision BioSciences: Q2 Earnings Snapshot - San Antonio Express-News
Precision BioSciences: Q2 Earnings Snapshot - New Haven Register
BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology - PR Newswire
Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update - CRISPR Medicine News
Precision BioSciences: Q2 Earnings Snapshot - The Advocate
Precision BioSciences: Q2 Earnings Snapshot - San Francisco Chronicle
Precision BioSciences (DTIL) Tops Q2 Earnings and Revenue Estimates - Yahoo Finance
Precision BioSciences: Q2 Earnings Snapshot - The Washington Post
Precision BioSciences: Q2 Earnings Snapshot - WRAL News
Precision BioSciences: Q2 Earnings Snapshot - The Daily Reflector
Precision Biosciences Inc Stock (DTIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):